XML 62 R49.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Acquisition and Disposition - Additional Information (Details) |  | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Sep. 08, 2023 USD ($) item $ / shares shares | Jun. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 26, 2024 USD ($) | Mar. 01, 2024 USD ($) | Dec. 31, 2023 USD ($)
Surface Acquisition |  |  |  |  |  |  |  |  |
Cash consideration |  |  |  |  |  |  |  | $ 170,000,000.0 |
Pretax profit (loss) |  | $ (12,921,000) |  | $ (42,869,000) | $ 89,954,000 | $ (118,598,000) |  |  |
TSA receivables, net |  | 138,317,000 |  |  | 138,317,000 |  |  |  |
TSA payables and other accrued liabilities |  | 133,536,000 |  |  | 133,536,000 |  |  |  |
Additional consideration |  |  |  |  |  |  |  | 17,800,000 |
Goodwill |  |  |  |  |  |  |  |  | $ 943,000
Net impairment charge |  |  |  |  | 6,772,000 |  |  |  |
Contingent consideration, current |  |  |  |  |  |  |  |  | $ 3,300,000
Out-license - Novartis Institutes |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Impairment charge |  |  | $ 10,600,000 |  |  |  |  |  |
CIMERLI Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Cash consideration |  |  | 187,800,000 |  |  |  |  | 170,000,000.0 |
Gain on sale transaction |  |  | 153,600,000 |  |  |  |  |  |
Transaction costs |  |  | 7,200,000 |  |  |  |  |  |
Pretax profit (loss) |  |  |  | 2,700,000 | 7,400,000 | (1,200,000) |  |  |
TSA receivables, net |  | 138,000,000.0 |  |  | 138,000,000.0 |  |  |  |
TSA payables and other accrued liabilities |  | 133,300,000 |  |  | 133,300,000 |  |  |  |
Additional consideration |  |  |  |  |  |  |  | $ 17,800,000 |
Retention bonus |  | 10,000,000.0 |  |  | 10,000,000.0 |  |  |  |
Income under TSA |  | 800,000 |  |  | 1,100,000 |  |  |  |
YUSIMRY Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Cash consideration |  | 40,000,000.0 |  |  | 40,000,000.0 |  | $ 40,000,000.0 |  |
Inventory purchase commitments |  |  |  |  |  |  | $ 17,000,000.0 |  |
Gain on sale transaction |  | 22,900,000 |  |  |  |  |  |  |
Transaction costs incurred |  | 900,000 |  |  |  |  |  |  |
Transaction costs unpaid |  | 900,000 |  |  | 900,000 |  |  |  |
Pretax profit (loss) |  | 900,000 |  | $ 800,000 | 1,400,000 | $ (10,100,000) |  |  |
TSA receivables, net |  | 300,000 |  |  | 300,000 |  |  |  |
TSA payables and other accrued liabilities |  | $ 300,000 |  |  | $ 300,000 |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares | 0.1960 |  |  |  |  |  |  |  |
Share price | $ / shares | $ 5.2831 |  |  |  |  |  |  |  |
Contingent value right per share | item | 1 |  |  |  |  |  |  |  |
Contingent value rights payment period | 10 years |  |  |  |  |  |  |  |
Goodwill | $ 0 |  |  |  |  |  |  |  |
Business Combination, Number of Out Licensed Partnership Program | item | 2 |  |  |  |  |  |  |  |
Fair value of the contingent consideration |  |  | 3,800,000 |  |  |  |  |  |
Contingent consideration, current |  |  | 0 |  |  |  |  |  |
Surface Acquisition | Out-license - Novartis Institutes |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Net impairment charge |  |  | $ 6,800,000 |  |  |  |  |  |
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] |  |  | Selling General And Administrative Expense |  |  |  |  |  |
Impairment charge |  |  | $ 10,600,000 |  |  |  |  |  |
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] |  |  | Selling General And Administrative Expense |  |  |  |  |  |
Surface Acquisition | Surface GSK Agreement |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Milestone and royalty based CVR payments (as percent) | 70.00% |  |  |  |  |  |  |  |
Surface Acquisition | Surface's SRF114 proprietary drug product candidate |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Upfront payment based CVR payments (as percent) | 25.00% |  |  |  |  |  |  |  |
Surface Acquisition | Surface's SRF388 proprietary drug product candidate |  |  |  |  |  |  |  |  |
Surface Acquisition |  |  |  |  |  |  |  |  |
Upfront payment based CVR payments (as percent) | 50.00% |  |  |  |  |  |  |  |

X
- Definition The payment period of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of milestone and royalty based payments payable as part of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of upfront payments payable as part of contingent value rights under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of contingent value rights issuable in consideration for each share under business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationConsiderationContingentValueRightPerShare
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of outlicensed partnership program in a business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued in exchange of each share of acquiree in a business combination. + References No definition available. + Details
Name: | chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree
Namespace Prefix: | chrs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of additional consideration received or receivable for product inventory and prepaid manufacturing assets, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of consideration in the form of inventory purchase commitments assumed as part of the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationConsiderationInFormOfInventoryPurchaseCommitments
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsIncurred
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of unpaid transaction costs incurred by the company for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | chrs_DisposalGroupIncludingDiscontinuedOperationTransactionCostsUnpaid
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of Impairment of out-license asset and remeasurement of CVR liability, net. + References No definition available. + Details
Name: | chrs_ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transition services agreement payables classified as current. + References No definition available. + Details
Name: | chrs_TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transition services agreement receivable current. + References No definition available. + Details
Name: | chrs_TransitionServicesAgreementReceivableCurrent
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unpaid transaction costs and retention bonuses committed to pay. + References No definition available. + Details
Name: | chrs_UnpaidTransactionCostsAndRetentionBonusesPayable
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliOphthalmologyFranchiseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_YusimryImmunologyFranchiseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |